Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
East Syracuse site to serve as the LOTTE Center for North America Operations for LOTTE’s biologics contract development and manufacturing organization (CDMO) business
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
As part of the celebrations, the Institute organised a series of activities in the run up to International Nurses Day which is observed on 12th May every year
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
Revolutionary ovarian cancer rapid test available Q4 2022
The company exports mobile surgery equipment to over 100 countries from Pune
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
Subscribe To Our Newsletter & Stay Updated
